Connective Tissue Growth Factor Is a Novel Prodepressant

Area of Science:

• Neuroscience
• Molecular Biology
• Psychiatry

Background:

• Major depressive disorder (MDD) is linked to altered growth factor levels.
• While downregulation is studied, upregulated growth factors like CTGF may be key therapeutic targets.
• CTGF's role in negative affect is suggested by animal models.

Purpose of the Study:

• To investigate connective tissue growth factor (CTGF) as a potential therapeutic target for major depressive disorder.
• To examine CTGF expression in human brain tissue and animal models of depression and anxiety.
• To evaluate the therapeutic potential of an anti-CTGF antibody (FG-3019).

Main Methods:

• CTGF gene expression analysis in postmortem human amygdala from MDD patients and controls.
• Evaluation of CTGF expression in rat models, including those bred for anxiety and novelty-seeking behaviors.
• Assessment of CTGF changes following social defeat stress and early-life fibroblast growth factor 2 treatment.
• Testing the effects of CTGF administration and anti-CTGF antibody (FG-3019) treatment on depressive behaviors in rats.

Main Results:

• Significantly increased CTGF expression in the amygdala of individuals with MDD.
• Elevated CTGF levels in the dentate gyrus of high-anxiety rats and following social defeat stress.
• Early-life fibroblast growth factor 2 treatment reduced CTGF expression and anxiety-like behavior.
• CTGF administration induced depression-like behavior in rats; FG-3019 treatment demonstrated antidepressant effects.

Conclusions:

• Connective tissue growth factor (CTGF) is implicated as a prodepressant molecule.
• CTGF represents a novel therapeutic target for major depressive disorder.
• Targeting CTGF may offer a new strategy for antidepressant drug development.